The Emerging Infections Program used C. diff infections at 10 U.S. sites to estimate the national burden of C. diff through infection rates, recurrences, hospitalizations and hospital deaths from 2011 through 2017.
The estimated national number of C. diff infections and associated hospitalizations decreased over the five years, mostly because of the decline in healthcare-associated infections.
The study found 15,461 C. diff cases in 2011 at the 10 sites, with 10,177 healthcare-associated C. diff infections. In 2017, there were 15,512 total C. diff cases at the 10 sites, with 7,973 healthcare-associated cases. The estimated C. diff national burden decreased by 24 percent from 2011-17. The national burden of healthcare-associated C. diff infections decreased by 36 percent, whereas the community-associated rate was unchanged. The estimated number of hospitalizations for C. diff infections decreased by 24 percent over the five years.
More articles on infection control:
CDC: 3 ways to decontaminate respirators
Talking, breathing could spread coronavirus, experts tell White House
Some COVID-19 patients only show digestive symptoms, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
